Business Description
StageZero Life Sciences Ltd
NAICS : 325413
SIC : 3912
ISIN : CA36870T2065
Description
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | -19.15 | |||||
| Debt-to-Equity | -0.19 | |||||
| Debt-to-EBITDA | -1.72 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -336.13 | |||||
| Beneish M-Score | -20.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 118.3 | |||||
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 29.4 | |||||
| 3-Year FCF Growth Rate | 35.6 | |||||
| 3-Year Book Growth Rate | 17.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | -2.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | |||||
| Quick Ratio | 0.02 | |||||
| Days Inventory | 9.39 | |||||
| Days Sales Outstanding | 26.5 | |||||
| Days Payable | 1202.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -45.9 | |||||
| Shareholder Yield % | -9.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 16.95 | |||||
| Operating Margin % | -96.72 | |||||
| Net Margin % | -101.72 | |||||
| FCF Margin % | -10.52 | |||||
| ROA % | -280.01 | |||||
| ROIC % | -99.74 | |||||
| ROC (Joel Greenblatt) % | -465.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.67 | |||||
| EV-to-EBIT | -4.17 | |||||
| EV-to-EBITDA | -4.38 | |||||
| EV-to-Revenue | 3.83 | |||||
| EV-to-FCF | -37.11 | |||||
| Earnings Yield (Greenblatt) % | -23.98 | |||||
| FCF Yield % | -4.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
StageZero Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.293 | ||
| EPS (TTM) (€) | -0.011 | ||
| Beta | 1.59 | ||
| Volatility % | 65.41 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 0.0175 | ||
| 12-1 Month Momentum % | -2.78 | ||
| 52-Week Range (€) | 0.0155 - 0.028 | ||
| Shares Outstanding (Mil) | 123.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
StageZero Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
StageZero Life Sciences Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
StageZero Life Sciences Ltd Frequently Asked Questions
What is StageZero Life Sciences Ltd(FRA:61N1)'s stock price today?
The current price of FRA:61N1 is €0.02. The 52 week high of FRA:61N1 is €0.03 and 52 week low is €0.02.
When is next earnings date of StageZero Life Sciences Ltd(FRA:61N1)?
The next earnings date of StageZero Life Sciences Ltd(FRA:61N1) is 2025-02-14 Est..
Does StageZero Life Sciences Ltd(FRA:61N1) pay dividends? If so, how much?
StageZero Life Sciences Ltd(FRA:61N1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers